A true story of corruption, greed and lust for power.
Names, dates, places, times, lies, legalized bribery, influence peddling, corrupt government agencies, bad drugs and bad people.
Now at Amazon:
Now at Amazon:
While investigating statins, we were faced with big words
like “3-Hydroxy-3-Methyl-Glutaryl Coenzyme-A reductase”, sometimes shortened to
“HMG-CoA reductase” or better yet “reductase”. What to do?
To be understood, this report had to be simple.
Here is simple: we got shafted. The NIH and associated
agencies blew over a half a billion dollars of our money. The FDA may as well
have not existed. We have been lied to, stolen from and poisoned by the
pharmaceutical industry.
No surprises here; business as usual.
Another part of biochemical language became apparent.
Biochemistry is riddled with words and phrases like, “may, might, could, this
might mean, putative (supposed), pleiotropic (many) and unknown mechanism”. The
chemist might describe it something like this: “a proliferation of putative,
pleiotropic inexactitudes”.
Is biochemistry an inexact science?
No. It is a science of proven results that are reproducible,
consistent and understandable.
When it comes to approving drugs for profit it is easy to obscure
proven results with caveats like “may or might or unknown mechanism”. After
all, that is the language of biochemistry. When seeking FDA approval, those
words become the lies of the pharmaceutical industry. Those words are honest
words for unproven science; those are words that cannot be trusted when money
is involved.
When it comes to drugs versus sound science, absolute
science can be quickly obscured by the smoke screen of relative statistics.
Statistics don't lie, but liars use statistics.
Conflicts-of-interest become the enemy of a universally accepted
proven scientific body of evidence. Absolute truths are buried by relative
lies.
All of lipid theory “evidence” linking cholesterol to
cardiovascular disease is based on relative statistics. True believers like
Steinberg have agendas.
True believers are a dangerous lot. They fought on both
sides in the crusades and presided over the Spanish Inquisition. They brought
the Nazis to power in Germany and brought down the twin towers on 9/11.
Steinberg and his comrades are the true believers of this
report. They skewed the statistics to save us from ourselves – even if it kills
us. They are like the religious right that brought us prohibition, Al Capone,
segregation and lynch mobs.
Scientists free of hidden agendas like Siperstein had proven
statins were deadly long before a corrupted FDA approved them. Steinberg infected
his colleagues and convinced the FDA that a deadly fungal toxin was good for
all of us.
The drug companies that sell statins benefit from relative
statistics used to obfuscate hard science. They dress it up with phrases like
“evidence-based medicine”, “peer-reviewed report” and “double-blind study.”
Dress up a pig, it is still a pig.
Misuse of statistics is a malignant cancer on medicine.
Two hundred million users at $2 per toxic dose and $400,000,000 per day yields enough gross resources to hire a whole army of ghostwriters to publish bogus claims and bury absolute science with relative statistics. This “malignancy” props up a $146,000,000,000 per year windfall to the drug industry—all built on lies.
This report tracks the liars and the lies about one of the
statin drugs (lovastatin) from one of the drug companies (Merck). This is because
lovastatin was the first of all the currently prescribed statins and Merck is
responsible for its approval.
In short:
- Statin research was
founded on scientific assumption and an agenda.
- Statins are dangerous
drugs developed in error for profit.
- Scientific evidence had
proven that statins were lethal years before lovastatin’s approval.
- Merck corrupted the
science and the scientists.
- The approval process was
so corrupted by Merck that lovastatin was bound to be approved.
- Merck lied.
- The FDA shirked its duty; neither safety nor
efficacy was proven for statins.
- Statins are derived from
fungal toxins that block cell growth and replication.
- Untold harm is being done
to millions of human beings.
All of this is recorded in and gleaned from the public
record.
In 1989, Thomas J. Moore wrote an investigative report
called “The Cholesterol Myth”. He reviewed all the statistics published on
three major NIH studies mounted with public funds (costing us over
$500,000,000). He converted those relative statistics into their most
understandable and absolute form. From
his work, the following is clear:
- There is no credible proof
that high blood cholesterol and cardiovascular disease (CVD) have a causal
connection.
- Diet and exercise do not
help.
- There is no good reason to
prescribe statins to anyone.
If there was any justification for lowering cholesterol from
NIH's $500,000,000 studies, and a safe way could be found, it should be
administered to only one small group of men aged 28 to 45. The entire myth was
built around that group.
Irrefutable, reproducible science proves statins are deadly
and LDL cholesterol is vital for life. Universal biochemistry convention proves
statins kill organs and organisms, one cell at a time.
This report expands on the following publicly recorded
events:
- 1957:
Japanese biochemist Akira Endo graduates from Tohoku University and joins
Sankyo Pharmaceuticals in Tokyo. He receives a PhD in 1966 from Tohoku for
his work at Sankyo.
- 1959:
FDA approves MER/29 as the first cholesterol-lowering drug that blocked
the mevalonate pathway and is an instant success.
- 1959-1961: Multiple reports are published hailing the benefits of MER/29 for lowering cholesterol.
- 1961:
A MER/29 lab worker complains to her husband that lab animal data is
falsified. Her husband, who car-pools with an FDA investigator, reports
his wife's complaint. FDA performs an unannounced record search.
- 1962:
MER/29 is removed from the market after FDA discovers the William S.
Merrell Company had omitted preclinical findings of cataracts in rats and
dogs, muscle wasting in monkeys and other falsified or unreported data.
- 1963:
A federal grand jury indictment is issued against Merrell Co. and some of
its employees. Scientists and executives plead “no contest”, which protects them against the
grand jury findings in subsequent class-action civil suits. Multi-millions
are awarded to the victims.
- 1960-1975:
Drug companies enter the “mycotoxin gold rush” after a fungal toxin
(aflatoxin) was found to cause cancer epidemics in grain-fed domestic trout
and turkeys.
- 1970:
Marvin Siperstein publishes his discovery that aflatoxin disrupts
cholesterol synthesis in cells.
- 1971:
Endo searches for cholesterol-lowering agents from fungal mycotoxins.
- 1976:
Endo extracts citrinin, a disease-causing mycotoxin from Penicillium citrinum. He discovers
that citrinin lowers blood cholesterol and publishes his report.
- 1976:
Endo abandons his work with citrinin because it is too toxic. He extracts
another mycotoxin from Penicillium
citrinum called “ML-236B” which proves less toxic than citrinin and
also lowers blood cholesterol. ML-236B becomes the first experimental
statin.
- 1976: Endo contacts Dr. Goldstein at a Dallas-based Merck supported lab. Goldstein expresses interest in ML-236B.
- 1976:
Merck contracts with Sankyo for the disclosure of information on ML-236B. Sankyo
believes that both companies will jointly develop ML-236B.
- 1977:
Endo, Brown and Goldstein publish a paper documenting how statins cause an
increase in reductase.
Statins are yet called “reductase inhibitors”
instead of “reductase stimulators”.
- 1978:
Merck develops their own statin. Sankyo cancels work with Merck. Endo
leaves Sankyo.
- 1979:
Endo patents another statin and sells it to Sankyo.
- 1979: Brown
and Goldstein's mentor, Marvin Siperstein, co-authors a paper with astronaut
Millie Hughes-Fulford. They explain how Endo's statin blocks DNA
replication in cells and kills them.
- 1980:
Brown and Goldstein co-author a paper explaining how statin-fed cells mutate
and make more reductase or die.
- 1980:
Sankyo cancels clinical trials on humans after half their lab dogs develop
cancer.
- 1980:
After receiving news of Sankyo’s decision to stop statin development,
Merck calls Sankyo. Sankyo refuses to talk with Merck. Merck stops statin
development.
- 1981:
Brown and Goldstein report on cell mutations induced by statins.
- 1982: Under arrangements approved by the FDA, Merck makes lovastatin available to Grundy, Bilheimer and Brown at Dallas for FH patients who had failed known treatment modalities. An IND (Investigational New Drug) permit is granted for human experimentation in Dallas.
- 1984:
Merck applies for an IND for lovastatin and a new drug application (NDA)
is approved in nine months – one of the shortest approval times for the
FDA since MER/29.
- 1985:
The NIH launches the National Cholesterol Education Program (NCEP).
Steinberg positions his colleague Grundy to chair the NCEP.
- 1985: Merck consultants Brown and
Goldstein receive the Nobel Prize in Medicine for statin-related research.
Their papers no longer report on statins’ deadly effects.
- 1987
(February 19): Brown and Steinberg represent Merck at the FDA advisory
committee meeting on lovastatin. There is no disclosure on the increase in
reductase and resultant cell injuries from mevalonate deprivation that are
said, by Merck's MacDonald and Tobert, to be due to an unknown mechanism.
- 1987
(August): Lovastatin is FDA approved.
- 1987
(October): NCEP publishes cholesterol (statin) treatment guidelines in the
American Heart Association’s (AHA’s) widely read “Circulation” magazine.
The president of the AHA, Tony Gotto, is Merck’s consultant.
- 1990: The
NIH convenes a panel to discuss the possibility that decreasing
cholesterol levels might be intrinsically dangerous. The panel concludes
that the evidence cannot be ruled out but dismisses it anyway.
- 2001: Bayer's “super-statin” Baycol is recalled after
multiple deaths are attributed to the drug.
Greed smothers the conscience. Drug cartels, legal or
illegal, pursue another agenda that rivals the evil of true believers. The
vampire turns his hypnotic gaze on his victim: “You will live forever,” he whispers. He does not rightfully hiss, “You
will sleep alone in a casket and never see the sun again.”
Today, statins remain the most insidiously
dangerous and best-selling drug in the world.
In this book, “cardiovascular disease” is
abbreviated as CVD. CVD includes coronary heart disease, atherosclerosis
(hardening of the arteries), heart failure, high blood pressure and stroke.